David Ricks - Eli Lilly CEO Chairman
| LLY Stock | 764.20 33.50 4.58% |
Insider
David Ricks is CEO Chairman of Eli Lilly and
| Age | 55 |
| Phone | 317 276 2000 |
| Web | https://www.lilly.com |
Eli Lilly Management Efficiency
The company has return on total asset (ROA) of 0.11 % which means that it generated a profit of $0.11 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6267 %, meaning that it generated $0.6267 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kristy Keyte | Treasury Wine Estates | N/A | |
| BEng BE | Treasury Wine Estates | N/A | |
| BALLB BA | Treasury Wine Estates | N/A | |
| Fumio Arai | Shin Etsu Chemical Co | N/A | |
| Toshiya Akimoto | Shin Etsu Chemical Co | N/A | |
| Meiko Koga | Sekisui Chemical Co | N/A | |
| Yukihito Adachi | Shin Etsu Chemical Co | N/A | |
| Yoshiyuki Hirai | Sekisui Chemical Co | 60 | |
| Tal Darmon | Strategic Education | 48 | |
| Kazuya Murakami | Sekisui Chemical Co | 57 | |
| Tatsuya Nishida | Sekisui Chemical Co | N/A | |
| Ikusuke Shimizu | Sekisui Chemical Co | 59 | |
| Timothy MBA | Treasury Wine Estates | N/A | |
| Jen Towns | Strategic Education | N/A | |
| Keita Kato | Sekisui Chemical Co | 65 | |
| Lizette Esq | Strategic Education | 48 | |
| Futoshi Kamiwaki | Sekisui Chemical Co | 63 | |
| Yasuhiko Saitoh | Shin Etsu Chemical Co | 68 | |
| Michelle Brampton | Treasury Wine Estates | N/A | |
| Toshiyuki Kamiyoshi | Sekisui Chemical Co | 62 | |
| Toshiyuki Kasahara | Shin Etsu Chemical Co | N/A | |
Management Performance
| Return On Equity | 0.63 | |||
| Return On Asset | 0.11 |
Eli Lilly Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Ricks, CEO Chairman | ||
| Jacob Naarden, CEO VP | ||
| Alonzo Weems, VP Officer | ||
| Diogo Rau, VP Officer | ||
| Donald Zakrowski, Chief Fin | ||
| Anat Ashkenazi, VP CFO | ||
| Leigh Pusey, Sr Communications | ||
| Martin MIBS, VP Projects | ||
| Anat JD, Gen VP |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.63 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 337.36 B | |||
| Shares Outstanding | 950.3 M | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 84.33 % | |||
| Price To Book | 34.75 X | |||
| Price To Sales | 10.99 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.